PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib (Q40033522)
Jump to navigation
Jump to search
scientific article published on December 2007
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib |
scientific article published on December 2007 |
Statements
1 reference
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib (English)
1 reference
Matthew Meyerson
1 reference
Pasi A Jänne
1 reference
John V Heymach
1 reference
Jeffrey A Engelman
1 reference
Kreshnik Zejnullahu
1 reference
Christopher-Michael Gale
1 reference
Eugene Lifshits
1 reference
Andrea J Gonzales
1 reference
Takeshi Shimamura
1 reference
Feng Zhao
1 reference
Patrick W Vincent
1 reference
George N Naumov
1 reference
James E Bradner
1 reference
Irene W Althaus
1 reference
Geoffrey I Shapiro
1 reference
James M Nelson
1 reference
Kwok-Kin Wong
1 reference
1 December 2007
1 reference
1 reference
Identifiers
1 reference